Abstract
ADAM28 (a disintegrin and metalloproteinase 28) is over-expressed in non-small-cell lung cancer (NSCLC) with correlation to cancer cell proliferation, tumor size and lymph node metastasis. The present study was aimed to develop an enzyme-linked immunosorbent assay (ELISA) system for diagnosis and monitoring of NSCLC. Our ELISA specifically measured ADAM28, showing negligible cross-reactivity with other metalloproteinases. The ADAM28 level in the NSCLC tissue was remarkably 36.9-fold higher than that in the non-neoplastic lung tissue (p < 0.001). The serum level was significantly 4.6-fold higher in the NSCLC patients (5.41 8.62 ng/ml; n = 102) than in the control subjects (1.17 0.93 ng/ml; n = 20) (p < 0.001), and increased with progress of tumor stage (p < 0.001). The level was also significantly higher in the patients with recurrent carcinoma than the control (p < 0.001) and in the patients with lymph node metastasis than those without metastasis (p < 0.001). The sensitivity, false-negative rate and AUC for ADAM28 were better than those for carcinoembryonic antigen. The combination of both assays improved the sensitivity, specificity, false-positive and false-negative rates for NSCLC. There was a positive correlation between the ADAM28 level measured by ELISA system and the degree of immunostaining in the lung adenocarcinomas with a size of &20 mm in diameter. The adenocarcinoma patients showing the high immunohistochemical reaction exhibited a poorer disease-free survival than those with the lower immunoreactivity (n = 102; p < 0.05). These data demonstrate that our ELISA is specific and sensitive to monitor the levels of ADAM28 in the samples from NSCLC patients and suggest that ADAM28 is a useful serological and histochemical marker for NSCLC.
| Original language | English |
|---|---|
| Pages (from-to) | 1844-1856 |
| Number of pages | 13 |
| Journal | International Journal of Cancer |
| Volume | 127 |
| Issue number | 8 |
| DOIs | |
| Publication status | Published - 2010 Oct 15 |
Fingerprint
Keywords
- ADAM
- biological marker
- diagnosis
- lung cancer
- prognosis
ASJC Scopus subject areas
- Cancer Research
- Oncology
- Medicine(all)
Cite this
ADAM28 is a serological and histochemical marker for non-small-cell lung cancers. / Kuroda, Hiroaki; Mochizuki, Satsuki; Shimoda, Masayuki; Chijiiwa, Miyuki; Kamiya, Kazunori; Izumi, Yotaro; Watanabe, Masazumi; Horinouchi, Hirohisa; Kawamura, Masahumi; Kobayashi, Koichi; Okada, Yasunori.
In: International Journal of Cancer, Vol. 127, No. 8, 15.10.2010, p. 1844-1856.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - ADAM28 is a serological and histochemical marker for non-small-cell lung cancers
AU - Kuroda, Hiroaki
AU - Mochizuki, Satsuki
AU - Shimoda, Masayuki
AU - Chijiiwa, Miyuki
AU - Kamiya, Kazunori
AU - Izumi, Yotaro
AU - Watanabe, Masazumi
AU - Horinouchi, Hirohisa
AU - Kawamura, Masahumi
AU - Kobayashi, Koichi
AU - Okada, Yasunori
PY - 2010/10/15
Y1 - 2010/10/15
N2 - ADAM28 (a disintegrin and metalloproteinase 28) is over-expressed in non-small-cell lung cancer (NSCLC) with correlation to cancer cell proliferation, tumor size and lymph node metastasis. The present study was aimed to develop an enzyme-linked immunosorbent assay (ELISA) system for diagnosis and monitoring of NSCLC. Our ELISA specifically measured ADAM28, showing negligible cross-reactivity with other metalloproteinases. The ADAM28 level in the NSCLC tissue was remarkably 36.9-fold higher than that in the non-neoplastic lung tissue (p < 0.001). The serum level was significantly 4.6-fold higher in the NSCLC patients (5.41 8.62 ng/ml; n = 102) than in the control subjects (1.17 0.93 ng/ml; n = 20) (p < 0.001), and increased with progress of tumor stage (p < 0.001). The level was also significantly higher in the patients with recurrent carcinoma than the control (p < 0.001) and in the patients with lymph node metastasis than those without metastasis (p < 0.001). The sensitivity, false-negative rate and AUC for ADAM28 were better than those for carcinoembryonic antigen. The combination of both assays improved the sensitivity, specificity, false-positive and false-negative rates for NSCLC. There was a positive correlation between the ADAM28 level measured by ELISA system and the degree of immunostaining in the lung adenocarcinomas with a size of &20 mm in diameter. The adenocarcinoma patients showing the high immunohistochemical reaction exhibited a poorer disease-free survival than those with the lower immunoreactivity (n = 102; p < 0.05). These data demonstrate that our ELISA is specific and sensitive to monitor the levels of ADAM28 in the samples from NSCLC patients and suggest that ADAM28 is a useful serological and histochemical marker for NSCLC.
AB - ADAM28 (a disintegrin and metalloproteinase 28) is over-expressed in non-small-cell lung cancer (NSCLC) with correlation to cancer cell proliferation, tumor size and lymph node metastasis. The present study was aimed to develop an enzyme-linked immunosorbent assay (ELISA) system for diagnosis and monitoring of NSCLC. Our ELISA specifically measured ADAM28, showing negligible cross-reactivity with other metalloproteinases. The ADAM28 level in the NSCLC tissue was remarkably 36.9-fold higher than that in the non-neoplastic lung tissue (p < 0.001). The serum level was significantly 4.6-fold higher in the NSCLC patients (5.41 8.62 ng/ml; n = 102) than in the control subjects (1.17 0.93 ng/ml; n = 20) (p < 0.001), and increased with progress of tumor stage (p < 0.001). The level was also significantly higher in the patients with recurrent carcinoma than the control (p < 0.001) and in the patients with lymph node metastasis than those without metastasis (p < 0.001). The sensitivity, false-negative rate and AUC for ADAM28 were better than those for carcinoembryonic antigen. The combination of both assays improved the sensitivity, specificity, false-positive and false-negative rates for NSCLC. There was a positive correlation between the ADAM28 level measured by ELISA system and the degree of immunostaining in the lung adenocarcinomas with a size of &20 mm in diameter. The adenocarcinoma patients showing the high immunohistochemical reaction exhibited a poorer disease-free survival than those with the lower immunoreactivity (n = 102; p < 0.05). These data demonstrate that our ELISA is specific and sensitive to monitor the levels of ADAM28 in the samples from NSCLC patients and suggest that ADAM28 is a useful serological and histochemical marker for NSCLC.
KW - ADAM
KW - biological marker
KW - diagnosis
KW - lung cancer
KW - prognosis
UR - http://www.scopus.com/inward/record.url?scp=77956987886&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77956987886&partnerID=8YFLogxK
U2 - 10.1002/ijc.25212
DO - 10.1002/ijc.25212
M3 - Article
C2 - 20112342
AN - SCOPUS:77956987886
VL - 127
SP - 1844
EP - 1856
JO - International Journal of Cancer
JF - International Journal of Cancer
SN - 0020-7136
IS - 8
ER -